Ranbaxy is a research based pharmaceutical company with a strong focus on developing generics. The company has grown rapidly and is now India’s largest pharmaceuticals manufacturer. The company produces a range of different medications that cover many indications, including respiratory, cardiovascular, dermatology and infectious diseases.
Ranbaxy is headquartered in India, but has expanded its operations all over the world; 21 manufacturing facilities are now in production which are based across 8 countries and produce medications that are sold in over 150 countries.
The main mission for the partly generics giant is to provide quality and affordable pharmaceuticals to all its patients. It commits to this by employing a strong 14, 600 employee workforce that work on all different company areas from research to development and marketing. Ranbaxy now produce pharmaceuticals, generics, API’s, OTC products and ARV’s to its patients around the world.
The top therapeutic areas for Ranbaxy area are as follows;
- Anti- infectives
- Pain and musculoskeletal
- Central Nervous System
- Anti – retrovirals
Agreements with big pharma
Some of Ranbaxy’s products have attracted the attention of big pharma companies and been the subject of key global agreements, for example in 1999 Bayer AG signed a development and marketing agreement with Ranbaxy for an oral once-daily formulation of Ciprofloxacin and many years later Ranbaxy signed a major R&D agreement with GSK. More recently Ranbaxy became a member of the Japanese Daiichi Sankyo Group; a deal that elevated the company’s status and allowed it to become a more recognized name in Japan.
Partnering has become second nature to Ranbaxy thanks to these high profile agreements; Ranbaxy look for partners who match its value, ethics and commitment to patients. The company has many attributes to offer potential companies in return which include proven success in increasing market share, a large global reach, a dedicated global business development team and even a post alliance team that ensures the partnership is running smoothly once it is in place.
Ranbaxy has actually got partnering professionals based worldwide, the main business development team is based in India however the company has also got other executives dotted around in Africa (Johannesburg), UK (London), Russia (Moscow) and the US (New Jersey)
Clearly stated on the company’s website are the partnering targets of Ranbaxy moving forwards, it is looking to partner in the following indications;
- Metabolic Disorders
- Late-stage NMEs (Phase III onwards/Already Marketed) and Early-stage Super Generic products Biosimilars
- Platform Technologies
The Company is open to hearing from innovators with new concepts and provide the details of business contacts on its partnering page which can be found here.
Ranbaxy is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Ranbaxy presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Ranbaxy in person visit Current Partnering’s Event calendar.
Contacting Ranbaxy for partnering
Ranbaxy can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Ranbaxy’ business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Ranbaxy website has the email address and name of the contact responsible for partnering.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Ranbaxy’ business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Ranbaxy Linkedin Page
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above.
Ranbaxy partnering at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Report: Partnering Agreements with Ranbaxy 2009-2014
No M&A activity for Ranbaxy since 2009
Available reports from Current Partnering
Report: Partnering Agreements with Ranbaxy 2009-2014
Available resources for deal coverage for Ranbaxy
Read: more on Ranbaxy company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk